Core Viewpoint - The company announced that its wholly-owned subsidiary, Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., has completed a self-examination of tax matters and is required to pay a total of 16.56 million yuan in tax and late fees, which has been fully paid as of the announcement date [1]. Group 1: Basic Information - The total amount of tax and late fees to be paid is 16.56 million yuan, consisting of 11.23 million yuan in tax and 5.33 million yuan in late fees [1]. - The payment of the aforementioned tax and late fees has been completed as of the date of the announcement [1]. Group 2: Impact on the Company - According to relevant regulations, the payment of tax and late fees does not constitute a prior accounting error and will not involve retrospective adjustments to previous financial data [1]. - The tax payment will be included in the company's profit and loss for the year 2025, with the specific impact on net profit attributable to shareholders to be determined based on the audit data from the accounting firm [1]. - This tax payment matter will not affect the normal operations of the company [1].
安徽丰原药业股份有限公司 关于公司补缴税款的公告